Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis.
Chia Ching LeeYu Yang SoonCheng Nang LeongWee Yao KohJeremy Chee Seong TeyPublished in: Acta oncologica (Stockholm, Sweden) (2020)
There is low certainty in the evidence to suggest that positive PD-L1 expression is associated with inferior disease control and survival outcomes in patients with stage IV EGFR-mutated NSCLC treated with first-line EGFR TKIs.